Syncom Formulations (India) Ltd

Syncom Formulations (India) Ltd is rated Sell by MarketsMOJO, with this rating last updated on 08 August 2025. However, the analysis and financial metrics presented here reflect the company’s current position as of 23 January 2026, providing investors with the latest insights into its performance and outlook.

Syncom Formulations (India) Ltd, a player in the Pharmaceuticals & Biotechnology sector, recorded a fresh 52-week low of Rs.11.52 today, marking a significant decline amid broader market movements and company-specific performance trends.

Syncom Formulations (India) Ltd has touched a new 52-week low of Rs.12.3 today, marking a significant decline in its share price amid broader market pressures and company-specific performance trends.

Syncom Formulations (India) Ltd’s stock touched a fresh 52-week low of Rs.12.75 today, marking a significant decline amid broader market pressures and company-specific performance trends. The stock’s fall contrasts with the broader Sensex, which remains near its yearly highs despite recent volatility.

Syncom Formulations (India) Ltd has touched a new 52-week low of Rs.12.78 today, marking a significant decline in its stock price amid a broader market that remains resilient. The pharmaceutical company’s shares have been under pressure, reflecting a series of challenges that have weighed on investor sentiment over the past year.

Syncom Formulations (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 08 August 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 12 January 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Syncom Formulations (India) Ltd has reached a new 52-week low of Rs.13.23, marking a significant decline in its stock price amid a challenging year for the company. This fresh low reflects ongoing pressures within the Pharmaceuticals & Biotechnology sector, where the stock has underperformed relative to broader market indices.

Syncom Formulations (India) Ltd, a player in the Pharmaceuticals & Biotechnology sector, recorded a fresh 52-week low of Rs.13.72 on 8 Jan 2026, marking a significant decline in its stock price amid broader market fluctuations and company-specific performance trends.

Syncom Formulations (India) Ltd touched a new 52-week low of Rs.13.74 today, marking a significant decline in its stock price amid broader market fluctuations and company-specific performance trends.

Syncom Formulations (India) Ltd has touched a new 52-week low of Rs.14 today, marking a significant decline in its stock price amid broader market fluctuations and company-specific performance trends.

Syncom Formulations (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 08 Aug 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 January 2026, providing investors with an up-to-date view of the company's fundamentals, returns, and technical outlook.

Syncom Formulations (India) Ltd, a player in the Pharmaceuticals & Biotechnology sector, recorded a new 52-week low of Rs.14.04 today, marking a significant decline amid a series of consecutive losses over the past four trading sessions.

Syncom Formul., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting shifts in its fundamental and technical outlook. This adjustment follows a period marked by subdued financial growth and notable stock underperformance relative to broader market indices.

Syncom Formul., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting shifts in its fundamental and technical outlook. This adjustment comes amid subdued financial performance and a bearish technical stance, signalling a cautious market perspective on the stock’s near-term prospects.

Syncom Formulations (India) has reported impressive financial results for the quarter ending September 2025, with a 72.46% increase in Profit After Tax and a 25.87% rise in net sales. The company achieved its highest Return on Capital Employed and demonstrated strong operational efficiency, despite facing recent market challenges.